MX376783B - Liposomas que encapsulan un autoantígeno y su uso en la prevención y/o el tratamiento de enfermedades autoinmunes. - Google Patents

Liposomas que encapsulan un autoantígeno y su uso en la prevención y/o el tratamiento de enfermedades autoinmunes.

Info

Publication number
MX376783B
MX376783B MX2016009217A MX2016009217A MX376783B MX 376783 B MX376783 B MX 376783B MX 2016009217 A MX2016009217 A MX 2016009217A MX 2016009217 A MX2016009217 A MX 2016009217A MX 376783 B MX376783 B MX 376783B
Authority
MX
Mexico
Prior art keywords
liposome
pharmaceutical
veterinary compositions
provides
defined above
Prior art date
Application number
MX2016009217A
Other languages
English (en)
Other versions
MX2016009217A (es
Inventor
Sarabia Antonia María Cano
Comamala Daniel Maspoch
Autonell Irma Pujol
Autonell Juan Verdaguer
Pi Marta Vives
Original Assignee
Fundacio Inst Dinvestigacio En Ciencies De La Salut Germans Trias I Pujol
Fundacio Inst Catala De Nanociencia I Nanotecnologia
Inst Catalana Recerca Estudis Avancats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Inst Dinvestigacio En Ciencies De La Salut Germans Trias I Pujol, Fundacio Inst Catala De Nanociencia I Nanotecnologia, Inst Catalana Recerca Estudis Avancats filed Critical Fundacio Inst Dinvestigacio En Ciencies De La Salut Germans Trias I Pujol
Publication of MX2016009217A publication Critical patent/MX2016009217A/es
Publication of MX376783B publication Critical patent/MX376783B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un liposoma que encapsula un autoantígeno, en el que el liposoma tiene un tamaño comprendido entre 500 y 15000 nm y la membrana del liposoma comprende fosfatidilserina (PS) en una cantidad comprendida entre el 10 y el 40% en peso con respecto a la composición liposómica total de membrana. También se proporcionan composiciones farmacéuticas o veterinarias que comprenden una cantidad terapéuticamente eficaz de dicho liposoma. Además, la invención proporciona liposomas y composiciones farmacéuticas o veterinarias como se han definido anteriormente para uso como un medicamento, particularmente para el tratamiento de enfermedades autoinmunes. Finalmente la presente invención proporciona liposoma y composiciones farmacéuticas o veterinarias como se ha definido anteriormente para uso en la restauración de autotolerancia en un paciente que padece una enfermdad autoinmune.
MX2016009217A 2014-01-17 2015-01-16 Liposomas que encapsulan un autoantígeno y su uso en la prevención y/o el tratamiento de enfermedades autoinmunes. MX376783B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14151629 2014-01-17
PCT/EP2015/050747 WO2015107140A1 (en) 2014-01-17 2015-01-16 Liposome-based immunotherapy

Publications (2)

Publication Number Publication Date
MX2016009217A MX2016009217A (es) 2017-05-12
MX376783B true MX376783B (es) 2025-03-07

Family

ID=49949574

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009217A MX376783B (es) 2014-01-17 2015-01-16 Liposomas que encapsulan un autoantígeno y su uso en la prevención y/o el tratamiento de enfermedades autoinmunes.

Country Status (12)

Country Link
US (1) US12048765B2 (es)
EP (1) EP3094345B1 (es)
JP (2) JP6546195B2 (es)
CN (1) CN106061502B (es)
AU (1) AU2015206016B2 (es)
BR (1) BR112016016356B1 (es)
CA (1) CA2939435C (es)
ES (1) ES2672247T3 (es)
MX (1) MX376783B (es)
PL (1) PL3094345T3 (es)
TR (1) TR201807778T4 (es)
WO (1) WO2015107140A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3094345B1 (en) * 2014-01-17 2018-03-14 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Liposome-based immunotherapy
EP2918262B1 (en) * 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
EP3586300A4 (en) * 2017-02-24 2020-12-09 Ebner-Todd, Rene KITCHEN APPLIANCE AND NUTRITION MANAGEMENT
BR112022009934A2 (pt) * 2019-11-22 2022-08-09 Univ New York State Res Found Método para prevenir ou tratar diabetes tipo 1, e, composição compreendendo lipossomas
JP2025539844A (ja) 2022-11-23 2025-12-09 アヘッド セラピューティクス，エス．エル． 免疫寛容原性組成物
WO2025083024A1 (en) * 2023-10-16 2025-04-24 Universiteit Utrecht Holding B.V. Improved formulations of autoantigen conjugates

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
CN1138533C (zh) * 1996-09-13 2004-02-18 利普森有限公司 脂质体
CA2319928A1 (en) 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
EP1547581A1 (en) * 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
KR101215808B1 (ko) 2004-06-11 2012-12-26 도꾸리쯔교세이호징 리가가쿠 겐큐소 조절성 세포 리간드를 리포좀에 함유시켜 이루어지는 의약
CN101588813A (zh) * 2005-04-12 2009-11-25 杜克大学 诱导人类免疫缺陷病毒的中和抗体的方法
EP1909758A1 (en) 2005-08-02 2008-04-16 I.D.M. Immuno-Designed Molecules Process for the preparation of liposomal formulations
EP3424525A1 (en) * 2007-10-12 2019-01-09 Massachusetts Institute Of Technology Vaccine nanotechnology
AU2009214041A1 (en) 2008-02-14 2009-08-20 Katholieke Universiteit Leuven CD4+ T-cells with cytolytic properties
CN101502649B (zh) * 2008-06-23 2011-11-30 深圳职业技术学院 一种脂质体流感疫苗
EP3058953A1 (en) * 2009-07-07 2016-08-24 The Research Foundation Of State University Of New York Lipidic compositions for induction of immune tolerance
JP2014510045A (ja) * 2011-02-08 2014-04-24 ハロザイム インコーポレイテッド ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用
US9987354B2 (en) * 2011-04-29 2018-06-05 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells
US20150150996A1 (en) * 2012-06-06 2015-06-04 Northwestern University Compositions and methods for antigen-specific tolerance
EP3094345B1 (en) * 2014-01-17 2018-03-14 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Liposome-based immunotherapy

Also Published As

Publication number Publication date
PL3094345T3 (pl) 2018-11-30
AU2015206016B2 (en) 2020-07-23
CA2939435C (en) 2023-09-19
JP2019196363A (ja) 2019-11-14
CN106061502A (zh) 2016-10-26
MX2016009217A (es) 2017-05-12
EP3094345B1 (en) 2018-03-14
CN106061502B (zh) 2021-04-13
TR201807778T4 (tr) 2018-06-21
JP2017507171A (ja) 2017-03-16
CA2939435A1 (en) 2015-07-23
AU2015206016A1 (en) 2016-08-25
JP6546195B2 (ja) 2019-07-17
BR112016016356B1 (pt) 2023-12-26
EP3094345A1 (en) 2016-11-23
WO2015107140A1 (en) 2015-07-23
BR112016016356A2 (pt) 2017-10-03
US20160338953A1 (en) 2016-11-24
ES2672247T3 (es) 2018-06-13
US12048765B2 (en) 2024-07-30

Similar Documents

Publication Publication Date Title
MX376783B (es) Liposomas que encapsulan un autoantígeno y su uso en la prevención y/o el tratamiento de enfermedades autoinmunes.
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
IN2015DN00376A (es)
AU2017265937A1 (en) Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
TN2012000611A1 (en) Formulations of rifaximin and uses thereof
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
EA201492047A1 (ru) Пролипосомальные композиции тестостерона
EP4414376A3 (en) Novel depsipeptide and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX362485B (es) Nuevos inhibidores de rock.
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MX370953B (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
WO2015033302A3 (en) Fulvestrant compositions
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one

Legal Events

Date Code Title Description
FG Grant or registration